ValuEngine upgraded shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

ALDR has been the subject of several other reports. Leerink Swann reiterated an outperform rating and set a $32.00 price objective on shares of Alder Biopharmaceuticals in a research report on Monday, June 12th. Needham & Company LLC restated a buy rating and issued a $36.00 target price on shares of Alder Biopharmaceuticals in a research report on Friday, June 9th. Credit Suisse Group cut Alder Biopharmaceuticals from an outperform rating to a neutral rating and lowered their target price for the company from $30.00 to $17.00 in a research report on Wednesday, June 28th. Piper Jaffray Companies restated an overweight rating and issued a $47.00 target price on shares of Alder Biopharmaceuticals in a research report on Wednesday, June 28th. Finally, Wells Fargo & Company reaffirmed an outperform rating and set a $51.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 28th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $28.69.

Alder Biopharmaceuticals (NASDAQ:ALDR) opened at 12.45 on Friday. Alder Biopharmaceuticals has a 52 week low of $8.60 and a 52 week high of $34.30. The stock’s 50 day moving average price is $10.15 and its 200-day moving average price is $14.91. The stock’s market capitalization is $843.03 million.

Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, topping the consensus estimate of ($1.67) by $0.19. Alder Biopharmaceuticals had a negative net margin of 10,926.65% and a negative return on equity of 118.04%. The firm had revenue of $0.68 million during the quarter. During the same quarter last year, the company posted ($0.79) EPS. Alder Biopharmaceuticals’s revenue for the quarter was up 518.2% on a year-over-year basis. Equities research analysts expect that Alder Biopharmaceuticals will post ($5.60) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/alder-biopharmaceuticals-inc-aldr-upgraded-by-valuengine-to-sell.html.

In other news, Director Stephen M. Dow purchased 25,000 shares of the stock in a transaction dated Tuesday, July 18th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in Alder Biopharmaceuticals by 3,047.2% during the first quarter. Bank of Montreal Can now owns 5,602 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,424 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Alder Biopharmaceuticals by 145.2% during the first quarter. Russell Investments Group Ltd. now owns 39,579 shares of the biopharmaceutical company’s stock worth $823,000 after acquiring an additional 23,437 shares during the period. American Century Companies Inc. grew its holdings in Alder Biopharmaceuticals by 5.7% during the first quarter. American Century Companies Inc. now owns 70,486 shares of the biopharmaceutical company’s stock worth $1,466,000 after acquiring an additional 3,815 shares during the period. Bank of New York Mellon Corp grew its holdings in Alder Biopharmaceuticals by 4.6% during the first quarter. Bank of New York Mellon Corp now owns 210,401 shares of the biopharmaceutical company’s stock worth $4,377,000 after acquiring an additional 9,218 shares during the period. Finally, Swiss National Bank grew its holdings in Alder Biopharmaceuticals by 2.6% during the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock worth $1,380,000 after acquiring an additional 1,700 shares during the period. Institutional investors and hedge funds own 76.16% of the company’s stock.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.